

UPDATING ON LABORATORY DEVELOPMENTS ON ONCOLOGY: FROM CEA TO...

biology
methodology
clinical applications




JOLLY HOTEL AMBASCIATORI
TORINO, 7-10 NOVEMBER 1990



Editors

C. ROSSO - A. CELLERINO - G. L. TURCO
F. PECCHIO - M. RAPELLINO - G. C. TORRE

ONCOLOGY PROGRAMM TUMOUR MARKERS



STEP-BY-STEP
DIAGNOSTIC
APPROACH

CEA - M - K S
AFP - M - K S
FERRITINA - M
CA - 125 K
CA 15-3 K
GICA K
HTG K
PSA
B72.3 - M - K S

Immunoradiometric
assay for tumour
marker determination

UPDATING ON LABORATORY DEVELOPMENTS ON ONCOLOGY: FROM CEA TO...

biology
methodology
clinical applications

JOLLY HOTEL AMBASCIATORI
TORINO, 7-10 NOVEMBER 1990

Editors

C. ROSSO - A. CELLERINO - G. L. TURCO
F. PECCHIO - M. RAPELLINO - G. C. TORRE

COMMUNICATIONS



CONTENTS

THE JOURNAL OF NUCLEAR MEDICINE AND ALLIED SCIENCES

Vol. 34 - 1-314

Supplement to issue No. 4 (October-December, 1990)

Communications

Kinetic Use of Tumor Markers in the Follow-up of Patients Operated for Primary Breast Cancer M. GION, G. FILA, R. BIASIOLI, G. VIGNATI, R. MIONE, S. SARACCHINI, E. RINALDI, E. TESTA, G. BRUSCAGNIN	1-7
Perioperative Kinetic Evaluation of Tumor Markers in Breast and Colorectal Carcinoma M. GION, G. RUGGERI, R. MARCONATO, C. CASELLA, A. NOSADINI, G. LAFFRAN- CHINI, R. MIONE, S. BELLOLI, G. BRUSCAGNIN	9-12
Evaluation of CA 549 in Malignant Neoplasms of the Human Breast B. BAGNI, A. R. CAVALLINI, M. INDELLI, P. MALACARNE	13-16
Utilità e limiti del CA 15.3 nel carcinoma mammario M. ZANINELLI, M. A. BASSETTO, T. FRANCESCHI, M. LENOTTI, F. PANCHERI, A. CORGNATI, G. L. CETTO	17-19
CAM 26 and CAM 29: Methodological Evaluations and First Clinical Employment in Breast Cancer G. PRIOLO, F. PECCHIO, M. RAPELLINO, G. AIMO, F. SPERTINO, C. PEPE	21-23
Cea citosolico: fattore prognostico nel carcinoma mammario? (Esperienza personale su 76 casi) D. AMADORI, L. FRASSINETI, A. RICCOBON, A. VOLPI, M. VASINI, O. NANNI, W. ZOLI, G. PALLOTTI	25-26
Analisi delle relazioni fra Cea citosolico e parametri clinico-patologici e biologici in 167 casi di carcinoma primitivo della mammella A. RICCOBON, L. FRASSINETI, M. VASINI, A. VOLPI, G. PALLOTTI, E. FLAMINI, E. MAGNI, R. NUNZIATINI, D. AMADORI	27-28
Valutazione del MCA, CA 15.3, CA M26, CA M29, nel carcinoma della mammella C. BUMMA, A. M. BRAMARDI, G. LAURIA, P. ARESE, G. MARCHETTI	29-32
Osservazioni e considerazioni sul contributo diagnostico dei valori sierici dei marcatori tumorali nell'adenocarcinoma della mammella M. CIOFFI, M. FRATTA, D. DE LUCIA, F. BRESCIANI	33-34
Utilità clinica del CA M26 e CA M29 nel carcinoma della mammella M. QUARANTA, G. MICELLI, M. COVIELLO, A. DONADEO, A. LOZUPONE, F. SCHIT- TULLI	35-38
CA 549 (HybriBRESscan) in Breast Cancer E. H. COOPER, V. LAURENCE, A. K. HANCOCK, D. PARKER, M. A. FORBES ...	39-41
Breast Cancer and Tumor Markers E. CASTELLARO, S. FRANCIONI, M. PASTORE	43-47
Valutazione di un nuovo maker CA 549 verso il CA 15-3 nella patologia mammaria neo- plastica e non neoplastica M. DI SERI, A. MANNA, M. SCIO, G. G. MARCHEI, A. DE BENEDETTO, M. G. REALE	49
TPA e TPS nel follow-up del cancro della mammella: valutazioni preliminari M. SCIO, G. G. MARCHEI, A. SANTINI, B. AMOROSO, M. G. REALE, P. MARCHEI	51
Evaluation of MCA and CA 15-3 in Tissue and in Serum of Patients with Breast Carcinoma (Preliminary Results) G. REALE, M. R. GIOVAGNOLI, A. VECCHIONE, L. COSENTINO, F. BENCI, A. MANNA, G. MARCHEI, I. VITTORI, L. FRATI	53

CONTENTS (continuation)

TAF Test: A New Tumor Marker? W. TACCONE, M. BELLI, M. RICCIO	55-58
Breast Cancer Mucin Antigen (BCM) Determination by IMX: A Preliminary Study of Epidemiological Distribution of the Serum Levels in Gynecological Diseases G. C. TORRE, V. BARBETTI, E. LANFRANCO, M. ROBUTTI, M. FOGLIA, G. CORONGIU, G. P. VIGLIERCIO	59-62
Tumor Markers and Cervical Carcinoma W. TACCONE, M. BELLI, M. RICCIO	63-66
Echography and CA 125 in Ovarian Pathology: Preliminary Data of a New Score M. FOGLIA, P. G. VERRI, A. CALABRESE, F. CORONGIU, A. TARANI, M. L. MARGIARIA, A. DE PASCALE, D. TAGLIATI	67-70
CA 125 Serum Levels and Postpartum M. FOGLIA, P. G. VERRI, G. M. MICCA, M. TOPPINO, A. TARANI, D. TAGLIATI, A. DE PASCALE, F. CORONGIU	71-74
Protocollo per una corretta valutazione del CA 125 nelle tumescenze pelviche P. BONELLI, M. MELPIGNANO, S. PIOMBO, D. FRANCHINI, V. CONDEMI	75-78
Tumor Antigens CA 125 and CA 15-3 as Markers of Endometrial Adenocarcinoma L. BABILONI, A. RICCARDI, S. TATEO, F. PAVESI, M. LOTZNIKER, F. POLATTI	79-83
Diagnostic Value of Prostatic Acid Phosphatase and Prostate-Specific Antigen in Patients with Prostatic Cancer F. PAGANI, T. ZAMBOLIN, R. BONORA, M. PANTEGHINI	85-87
Valore della positività dei marcatori tumorali nei tumori germinali non seminomatosi del testicolo M. A. BASSETTO, T. FRANCESCHI, M. LENOTTI, F. PANCHERI, M. ZANINELLI, A. CORGNATI, G. L. CETTO	89-90
Patologie prostatiche: marcatori tumorali (PAP e PSA) ed età a rischio A. MANNA, L. TRASATTI, L. CIFALDI, G. G. MARCHEI, M. G. REALE, P. MARCHEI	91
Urinary Evaluation of Tumor-Associated Antigens in Bladder Urothelium Pathologies A. TIZZANI, G. CASETTA, A. CAVALLINI, P. PIANA, P. PIANTINO	93
Carbohydrate Antigen 19-9 Immunohistochemistry in Transitional Bladder Carcinoma A. TIZZANI, G. CASETTA, A. CAVALLINI, P. PIANA, P. PIANTINO, A. LINARI, A. PAGANI	95
Valori elevati di CA 19-9, CA 50 e CA 195 in pazienti con malattie benigne dell'albero biliare e del pancreas P. PIANTINO, A. FUSARO, A. RANDONE, A. CERCHIER, E. DAZIANO	97-102
CA 72-4, CA 195 and CA 19-9 as Diagnostic Aid in Gastric Carcinoma P. PIANTINO, A. RANDONE, A. FUSARO, A. CERCHIER, E. DAZIANO	103-106
Clinical Usefulness of CEA as Tumor Marker in Patients with Colorectal Cancer X. FILELLA, R. MOLINA, J. L. BEDINI, J. JO, J. JOSEPH, A.-M. BALLESTA	107-110
Tumor Associated Glycoprotein (TAG 72) in Gastric Cancer M. LOTZNIKER, F. PAVESI, M. SCARABELLI, G. L. VISCONTI, L. BACCHELLA, R. GINI, R. MORATTI	111-114

CONTENTS (continuation)

A Protocol of the Use of CEA in Colorectal Cancer M. J. DOMINGUEZ, A. LAMQUIZ	115-118
Il CA 195 nella nostra esperienza: confronto con il CA 19.9 M. CORREALE, I. ABBATE, A. PELLECCIA, G. GARGANO	119-122
CA 195 in Colorectal Cancer M. ONETTO, G. B. SECCO, R. FARDELLI, G. CAMERINI, L. DE SALVO, W. VENTRELLA, R. LIONETTO	123-126
Marcatori tumorali nel carcinoma mammario metastatico: correlazione con la risposta clinica Y. WINER, M. C. MARTINI, G. PASTORINO, L. MORAGLIO, M. VALLAURI, P. BRONDI, F. BREMA	127-130
Cancro del pancreas e della regione periampollare: utilità dei marker tumorali prodotti con la tecnica degli anticorpi monoclonali V. VALENZA, M. L. MAUSSI, G. D'ERRICO, G. F. LEMMO, D. FRONTERA, A. FERRANTE, I. SALETNICH, A. VALLI, M. QUARANTELLI	131-134
Utilità dell'antigene carcinoembrionario (CEA), dell'antigene polipeptidico tissutale (TPA), dell'enolasi (NSE) e della timidina-kinasi (TK) nel monitoraggio e nella prognosi del carcinoma polmonare primitivo G. DE ANGELIS, F. DE MARINIS, D. BIGIONI, M. R. MIGLIORINO, M. G. ALMA, F. PIGORINI	135-140
Clinical Value of Neuron Specific Enosale and Tissue Polypeptidic Antigen for the Management of Patients with Lung Cancer A. SPINAZZI, E. SORESI, U. BORGHINI, R. BOFFI, R. VIGORELLI, S. SCOCCIA	141-145
NSE and CEA Determination in Serum of Patients with Small Cell Lung Cancer M. RAPELLINO, F. PECCHIO, C. AROSIO, F. CONI, F. REVELLO, S. BALDI, E. SCAPATICCI, D. LIBERTUCCI, R. OBERT, R. PAGNI, A. CELLERINO	147-149
Soluble Interleukin-2 Receptor: A New Prognostic Marker in Lung Cancer? P. MARINO, G. BUCCHERI, A. PREATONI, D. FERRIGNO, P. CORI, A. ROSTI, R. MOZZI, G. A. MORONI	151-154
La risposta immunitaria anti-tumorale nei pazienti con colon-retto carcinoma (Valutazione pre e post-chirurgica) F. BRIVIO, P. LISSONI, G. M. ROSSI, A. MAGGIONI, P. MARZI, M. COLZANI, D. MASSIMINI, F. ARIASI, V. GIARDINI, A. ANGELINI, F. BORIN	155-159
IL-2 Receptors, NK and LAK Cytotoxicity of Lymphocytes in Breast Carcinoma During Prolonged Thymopentin Therapy C. MAZZARINO, A. NICOSIA, V. MONTE, S. PETRALIA, C. GARRAFFO, A. GIRLANDO, S. SANTORO, G. MALAPONTE	161-162
Interleukin-2 Soluble Receptor (s-IL 2R) and Lung Cancer F. PECCHIO, M. RAPELLINO, G. AIMO, S. BALDI, M. CUNAZZA, D. LIBERTUCCI, A. CAVALLO, A. OLIARO, R. PAGNI	163-167
Early Clinical Results with Anti-CEA F(ab')₂ Fragments Labelled with ^{99m}Tc E. SECCAMANI, C. BONINO, L. TARDITI, M. CAMAGNA, G. MOSCATELLI, P. RIVA	169-172
Human Gliomas Radioimmunoimaging with ¹³¹I BC-2 Murine IgG (Preliminary Report) S. LASTORIA, L. CASTELLI, E. VERGARA, E. SECCAMANI, C. BONINO, M. MARIANI, M. S. DE SANTI, A. DE SIMONE, A. AMBROSIO, L. ZARDI, M. SALVATORE	173-176

CONTENTS (continuation)

The Role of Circulating CA 15-3 Levels in Monitoring of Patients with Breast Cancer D. FRANCHINI, P. BONELLI, G. GAVARUZZI, G. UGOLOTTI	177-178
Increased Chemosensitivity of Hematopoietic Neoplasia in Response to Growth Factors (A Review) D. FERRERO, M. RAPELLINO, F. PECCHIO, G. MARLETTO, C. CIAIOLO	179-184
Langerhans Cell and HLA Class II Molecules Distribution in Lung Carcinoma A. COLI, G. BIGOTTI, T. CIONE	185-189
Application of Lectin Histochemistry for the Study of Uterine and Ovarian Neoplasms V. BYCHKOV	191-194
Determinazione della P-170 tramite C-219 D. VENARUCCI, V. VENARUCCI, P. CATALINI, A. ANCONETANI, A. VALLESE ..	195-198
Analisi dell'incidenza dell'HPV 16 in C.I.N. mediante sonde fredde a DNA D. VENARUCCI, A. ANCONETANI, V. VENARUCCI, D. BATTILÀ, P. CATALANI, A. VALLESE	199-202
The Proliferation Marker Concept with TPS as a Model (A Preliminary Report) B. BJÖRKLUND, V. BJÖRKLUND	203
Proteine fosforilate in tirosina nel carcinoma mammario umano S. BRETTI, A. P. M. CAPPA, P. M. COMOGGIO, M. F. DI RENZO	205-210
An High Performance IRMA for CEA Determination E. FERRARA, P. B. ROMELLI, R. RINGHINI	211
Characterization of <i>in vitro</i> Expressed Human α-Fetoprotein as Highly Reproducible Reference Material for Clinical Immunoassays M. F. TECCE, B. TERRANA, M. M. GIULIANI, C. CECCARINI	213-216
Assessment of Multidrug Resistance (MDR) by Immunohistochemistry in Breast Carcinoma: Correlation with Tumor Size and Regional Node Status G. CHIAPPETTA, A. M. BEVILACQUA, A. PICONE, G. RICCIO, G. BOTTI	217-219
Mammary Carcinoma: A Multiparametric (MDR-P-Glycoprotein Expression, Regional Node Status, Tumor Cells Kinetics and Receptor Status) and Immunohistochemical Study G. BOTTI, A. DE MATTEIS, G. CHIAPPETTA, G. D'AIUTO, G. ESPOSITO, A. PICONE	221-223
Immunoprecipitation Method for a Radioligand Binding Assay of Epidermal Growth Factor Receptor R. DITTADI, M. GION, A. BRAZZALE, G. BRUSCAGNIN	225-230
La β_2-microglobulina nelle gammopatie monoclonali A. ANANIA, G. CASCIO, S. ROSTAGNO, C. RICCI	231-233
Evaluation of Serum Tumor Markers in Head and Neck Cancer M. MARTIN, J. I. RAYO, J. R. G. TALAVERA, A. MUÑOZ, A. CAÑIZO	235-238
Comparison Between Various Tumor Marker M. PASTORE, A. SBAFFI, S. FRANCONI, E. CASTELLARO	239-250
Tumor Markers and Chemotherapy S. FRANCONI, M. PASTORE, E. CASTELLARO	251-259

CONTENTS (continuation)

Prestazioni analitiche del CEA MEIA IMX S. BONJEAN, M. CRISTOFERI, S. RATIBONDI	261-270
A New Method for the <i>in vitro</i> Transfer of Delayed Hypersensitivity by Dialysed Transfer Factor M. FAZIO, L. NEGRI, F. CALABRESE, F. CORREGGIA, S. GIACOMASSO, B. MASTROMATTEO	271-274
Valore del dosaggio dell'idrossiprolina (OH-P) urinaria in un gruppo di pazienti affetti da differenti neoplasie A. DE BENEDETTO, G. G. MARCHEI, G. CARDINALE, M. MICHETTI, P. MARCHEI, M. G. REALE	275
L'etica della ricerca in oncologia: dal laboratorio alla sperimentazione clinica V. MELE, L. PALAZZANI, E. SGRECCIA	277-279
Clinical and Laboratorial Remarks in the Measurements of Some Tumor Markers F. GIULIANI, G. NERI, M. BERTOLO, L. BINETTI, C. ROSSI	281-284
Gli indicatori tumorali CA 19-9, CA 125, CA 72-4 e CA 50 nella patologia neoplastica (Risultati di una esperienza triennale) M. FRATTA, M. CIOFFI, D. DE LUCIA, F. BRESCIANI	285-288
Comparison Between CEA and GICA in Patients with Advanced Cancer L. CAMOGLIANO, R. MASSACANE, M. L. GOGGI, M. D'ULIZIA, C. ARFINI, M. MASINO, E. PRIARONE, M. TACCHINO	289-290
Utilità del dosaggio del 5NU unitamente al CA 19-9 nella diagnostica e nel monitoraggio delle affezioni epatiche discariocinetiche D. SANTINI, G. G. MARCHEI, L. TRASATTI, M. DI SERI, M. G. REALE, L. FRATI	291
Evaluation of TAG-72 and CEA Tumor Markers in Sera of Patients with Gastrointestinal Adenocarcinomas F. GUADAGNI, M. ROSELLI, T. AMATO, M. R. ABBOLITO, M. COSIMELLI, E. MANNELLA, J. W. GREINER, J. SCHLOM	293-296
Significato prognostico dell'infiltrato macrofagico nel carcinoma laringeo V. FERRERO, B. MORRA, M. GARETTO, M. T. CARLEVATO, D. PACCHIONI, M. CERRATO, M. BUSSI, G. CORTESINA	297-300
Tissue CEA Concentration in Colorectal Carcinoma and in the Proximal Mucosa S. PORCIANI, A. BECCIOLINI, A. LANINI, L. BANDETTINI, P. BECHI, A. BENUCCI, M. TOMMASI	301-304
Clinical Applications of Immunoscintigraphy in Lung Cancer Staging P. ANTONACCI, M. BELLÒ, C. CASADIO, G. CASTELLANO, A. CAVALLO, R. CIANCI, G. MARTA, M. MOLINATTI, F. PECCHIO, V. PODIO, M. RAPELLINO, G. L. TURCO	305
Successful Imaging of Pancreatic Cancer by anti-CEA F023C5 P. ANTONACCI, M. BELLÒ, M. BESSONE, G. CASTELLANO, G. CEPPI, G. MARTA, F. OLIVIERI, V. PODIO, E. SECCAMANI, G. L. TURCO	307
Evaluation of the New IMx SCC Test B. LEICHTWEIS, L. LENNARTZ, W. EBERT	309-313

KINETIC USE OF TUMOR MARKERS IN THE FOLLOW-UP OF PATIENTS OPERATED FOR PRIMARY BREAST CANCER

M. Gion¹, G. Fila², R. Biasioli³, G. Vignati⁴, R. Mione¹, S. Saracchini², E. Rinaldi³, E. Testa⁴, G. Brusca²

¹Centro Regionale Indicatori Biochimici di Tumore e ²Divisione di Radioterapia, Centro Oncologico Multizonale, Ospedale Civile, ULSS 16, Venezia. ³Divisione Medicina I e ⁴Laboratorio di Analisi, Ospedale Fornaroli, ULSS 72 Magenta.

INTRODUCTION

The clinical role of systemic therapies for metastatic breast cancer is currently under debate. Both death statistic studies (1-2) and clinical studies on patients with advanced breast cancer (3-7) suggested that the effect of therapies on patient survival is indeed very poor. On the basis of these findings the usefulness of the instrumental and laboratory follow-up programs for breast cancer has been questioned because the early detection of relapse does not affect significantly the prognosis of the disease (8-9).

Some authors report an improvement of survival due to the early detection of the recurrence if the disease was treated when still asymptomatic (10-12). However, the apparent gain in survival could have been ascribed to a longer lead time (8,13), that is, both patients and the medical staff were aware of the recurrence for longer time when asymptomatic disease had been identified.

The role of tumor markers is similar to that of other instrumental or laboratory tests. Actually, they are very effective, because they recognize the disease progression in a high percentage of cases. Moreover, in many instances tumor marker levels increase before any other clinical or instrumental sign of relapse. However, their use does not affect the overall survival. Tumor marker increases above the cutoff level are indeed very early, but at the present time, patients are treated only on the basis of clinical or instrumental evidence of relapse.

The aim of the present study is to verify if a kinetic evaluation of tumor markers during the follow-up may provide a long lead time with adequate accuracy performances, with the goal of the possible treatment of the relapse only on the basis of a biochemical identification.

MATERIALS AND METHODS

So far, 269 patients radically operated for primary breast cancer had been included in the study. Patients were divided into two groups, with high and low risk of relapse respectively, according to criteria shown in Table I.

The timing of the follow-up, as well as the instrumental tests currently requested, were not modified.

In high risk patients serum samples were collected three times within the month preceeding each clinical examination. In low risk patients a single serum sample was obtained before each clinical examination.

Serum samples were divided into several aliquots and stored at -70°C. CA15.3 and CEA were measured with commercially

available methods. When more samples were obtained from the same patient they were assayed in the same run. Assay precision was monitored by precision profiles.

Kinetic evaluation of tumor markers (three points within one month). Tumor marker variations were considered significant when the three serial points showed a progressive increase with the difference between the first and the third determination being higher than three times the coefficient of variation expected at a given dose. Patient follow-up was performed on the basis of tumor markers as shown in Table II.

Single sample (cutoff based) evaluation of tumor markers confirmed through kinetic study. In low risk patients tumor marker levels were evaluated according to the standard dichotomic criteria, based on a positive/ negative cutoff level. However, instead of a single cutoff point, two different levels were used: 1) normality threshold, calculated on the basis of tumor marker distribution in healthy subjects, that is the traditional cutoff value; and 2) alert threshold which was calculated on the basis of tumor marker levels found in patients with metastatic breast cancer. The threshold levels decision rule was used in the scheme shown in Table III in which the positivity detected using the cut-off criteria was confirmed through kinetic evaluation.

RESULTS

Low Risk Group. Among the 269 patients evaluated, 260 were free of disease, and 9 had clinical and/or instrumental sign of relapse.

Table IV summarizes tumor marker pattern in cases without evidence of disease. In the majority of cases CA15.3 and CEA showed values below the normality threshold.

In a second group CA15.3 in 9 cases and CEA in 10 showed values higher than the normality threshold; the kinetic evaluation on serial samples did not show any significant increase in tumor marker levels. The kinetic criteria is therefore in accordance with clinical conditions and suggests that cutoff based positivity should be considered as a false positivity.

In a third group of patients (3 for CA15.3 and 1 for CEA) tumor markers were higher than the normality threshold and showed a further increase during the following months. These patients should be considered as bearing occult disease and are currently evaluated each month.

The behavior of tumor markers in the 11 patients which relapsed is shown in Table V. CA15.3 was below the cutoff in 4 cases in one of which the marker value increased significantly within one month. In 5 cases CA15.3 was above the normality threshold. In 3 of these cases the markers showed a further increase, in 2 others no significant variations were found. Similar patterns were found for CEA which showed however a high number of cases below the cutoff level in which the kinetic was positive.

No preliminary results are yet available for the 25 patients at high risk of relapse so far evaluable. Indeed, the study



protocol set up for the high risk group was started later with the aim of enhancing the diagnostic sensitivity of the markers.

DISCUSSION

In the present study we used kinetic criteria to verify the biological meaning of tumor marker positivity. When tumor markers were above the cutoff level, two different kinetic patterns were identified. In the first, tumor marker levels increased significantly within one month; in the second, tumor marker levels did not show significant variations. The two patterns were identifiable both in patients without evidence of relapse and in those with disease progression. In both groups the increase of tumor marker levels should indicate the presence of a tumor secreting the tumor marker. Therefore, in patients apparently free of disease this pattern should be an early indicator of the relapse. Cases with markers above the cutoff which do not show any increase should either represent false positive cases or indicate tumors with a slower production and/or secretion rate of the marker. The clinical evaluation of patient follow-up will indicate which of the above hypothesis is more probable. Moreover, the serial determination of tumors marker in patients with high risk of relapse will provide further insight into tumor marker kinetic behavior.

REFERENCES

1. Levin DL, Gail MH, Kessler LG, et al. A model for projecting cancer incidence and mortality in the presence of prevention and treatment programs. NCI Monogr 1986; 2: 83.
2. La Vecchia C, Decarli A, Cislaghi C. Changes in breast cancer mortality in Italy. Eur J Cancer Clin Oncol 1988; 24 (2): 275.
3. Rouesse J, Friedman S, Guash-Jordan I, Hacene K, Brunet M. Survival effect of systematic therapy on patients developing metastatic breast carcinoma. Breast Cancer Res Treat 1990; 15: 13.
4. Patel JK, Nemoto T, Vezeridis M, et al. Does more intensive palliative treatment improve overall survival in metastatic breast cancer patients? Cancer 1986; 57: 567.
5. Powels TJ, Smith IE, Ford HT, et al. Failure of chemotherapy to prolong survival in a group of patients with metastatic breast cancer. Lancet 1980; 1: 580.
6. Paterson AHG, Szafran O, Cornish F, et al. Effect of chemotherapy on survival in metastatic breast cancer. Breast Cancer Res Treat 1981; 1: 357.
7. Devitt JE, Advent DA. Effect of current palliative treatment on the survival of patients with breast cancer. Can J Surg 1977; 20: 46.

8. Tomin R, Donegan WL. Screening for recurrent breast cancer. Its effectiveness and prognostic value. J Clin Oncol 1987; 5: 62.

9. Ciatto S, Rosselli Del Turco M, Pacini P, et al. Early detection of breast cancer recurrences through periodic follow-up. Is it useless? Tumori 1985; 71: 325.

10. Orniston MC, Timoney AG, Quieshi AR. Is follow-up of patients after surgery for breast cancer worthwhile? J R Soc Med 1985; 78: 920.

11. Umbach GE, Holzki C, Bender HG. Postoperative follow-up and clinical outcome in patients treated for breast cancer. Proc Am Soc Clin Oncol 1987; 6: A 217.

12. Zwaveling A, Albers GH, Felthuis W, Hermans J. An evaluation of routine follow-up for detection of breast cancer recurrences. J Surg Oncol 1987; 34: 194.

13. Sterer M, Rosen HR. Influence of early Diagnosis on prognosis of recurrent breast cancer. Cancer 1989; 64: 1128.

TABLE I. Subdivision of patients included in the study in relation to the probability of relapse.

PROBABILITY OF RELAPSE	TIME FROM MASTECTOMY	AXILLARY STATUS	MENOPAUSAL STATUS	ER and/or PgR
LOW	>5 years	+ or -	PREM or POSTM	+ or -
	≤5 years	-	POSTM	+ or -
		-	PREM	+
HIGH	≤5 years	+	PREM or POSTM	+ or -
		-	PREM	-

TABLE II. Kinetic use of tumor markers in patients with high risk of relapse.




TABLE III. Dichotomic/Kinetic use of tumor markers in patients with low risk of relapse.




TABLE IV. Tumor marker patterns in patients without evidence of relapse

	CUTOFF-	CUTOFF+ KINETIC-	CUTOFF+ KINETIC+
CA15.3	248	9	3
CEA	249	10	1

- CUTOFF+: values above the normality threshold (31 U/ml for CA15.3, 5 ng/ml for CEA).
- KINETIC+: cases in which tumor markers increased within one month more than three times the coefficient of variation expected.

TABLE V. Tumor marker patterns in patients in which relapse was identified simultaneously or after tumor marker increase

	CUTOFF- KINETIC-	CUTOFF+ KINETIC-	CUTOFF- KINETIC+	CUTOFF+ KINETIC+
CA15.3	3	2	1	3
CEA	1	1	4	3

- CUTOFF+: values above the normality threshold (31 U/ml for CA15.3, 5 ng/ml for CEA).
- KINETIC+: cases in which tumor markers increased within one month more than three times the coefficient of variation expected.

PERIOPERATORY KINETIC EVALUATION OF TUMOR MARKERS IN BREAST AND COLORECTAL CARCINOMA

M. Gion¹, G. Ruggeri², R. Marconato³, C. Casella⁴, A. Nosadini³, G. Laffranchini⁴, R. Mione¹, S. Belloli², G. Brusca¹.

¹Centro Regionale Indicatori Biochimici di Tumore, Divisione di Radioterapia e ³Divisione di Chirurgia Generale, Ospedale Civile, Venezia. ²Istituto di Chimica e Propedeutica Biochimica e ⁴Istituto di Patologia Chirurgica, Università di Brescia.

INTRODUCTION

A great number of studies are continually published in which tumor markers are evaluated as qualitative parameters categorized using a conventional cutoff value. Different tumor markers are compared on the basis of their performance characteristics, that is sensitivity, specificity, positive and negative predictive values, which are calculated using the cutoff point. However, the use of a dichotomic criteria in the clinical utilization of tumor markers suffers two main drawbacks:

- 1) differences in the subjects selected as control group may account for differences in the performance characteristics of a given tumor marker;
- 2) quantitative variations below the cutoff point are usually unrecognized.

In the present investigation perioperative variations of tumor marker serum levels were evaluated in patients radically operated for breast and colorectal cancer. The aim of the study is to verify the possibility of identifying any significant decrease of tumor markers due to the tumor resection, independently from the preoperative positivity or negativity of the marker.

PATIENTS AND METHODS

Forty one patients mastectomized for primary breast cancer and 60 patients radically resected for colorectal carcinoma have been so far evaluated. Serum samples for tumor marker assays were collected before, 10 and 30 days after tumor resection and stored at -70 C°. We measured serum levels of CEA and CA15.3 in breast cancer, CEA and CA19.9 in colorectal cancer. Both intra-assay and inter-assay variability of the evaluated tumor marker were below 10% when measured at three different dose levels. Assay precision was also monitored by precision profiles. The variation of tumor marker levels after the surgery was considered significant when it was higher than three times the coefficient of variation expected at a given dose level.

RESULTS

The distribution of positive and negative cases according to both cutoff point and kinetic criteria showed four different patterns, which are summarized in Table I for breast cancer and in Table II for colorectal cancer.